Recombinant Plasma Gelsolin Replacement for Cystic Fibrosis and Bronchiectasis is under clinical development by BioAegis Therapeutics and currently in Phase I for Bronchiectasis. According to GlobalData, Phase I drugs for Bronchiectasis have a 65% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Recombinant Plasma Gelsolin Replacement for Cystic Fibrosis and Bronchiectasis’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Recombinant Plasma Gelsolin Replacement for Cystic Fibrosis and Bronchiectasis overview

Recombinant plasma gelsolin (pGSN) is under development for the treatment of idiopathic bronchiectasis and lung injury in antibiotic resistant pneumonia . It is administered through intravenous route.  It is a recombinant endogenous human protein and a key component of the innate immune system. The drug candidate is developed based on plasma gelsolin technology. It was also under development for the treatment of respiratory symptoms of cystic fibrosis

BioAegis Therapeutics overview

BioAegis Therapeutics that involves in developing therapeutics for infectious, inflammatory and degenerative diseases based on the platform of plasma gelsolin. The company is headquartered in North Brunswick, New Jersey, the US.

For a complete picture of Recombinant Plasma Gelsolin Replacement for Cystic Fibrosis and Bronchiectasis’s drug-specific PTSR and LoA scores, buy the report here.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.